Reduction of anionic sites in the glomerular basement membrane by heparanase does not lead to proteinuria

Kidney International

Volumn 73, Issue 3, 2008, Pages 278-287

  Van Den Hoven, M J ^a   Wijnhoven, T J ^a,b   Li, J P ^c   Zcharia, E ^d   Dijkman, H B ^b   Wismans, R G ^a   Rops, A L ^a   Lensen, J F ^a   Van Den Heuvel, L P ^b   Van Kuppevelt, T H ^a   Vlodavsky, I ^e   Berden, J H M ^a   Van Der Vlag, J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UPPSALA UNIVERSITY   (Sweden)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^e TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Glomerular filtration barrier; Renal function; Transgenic mouse

Indexed keywords

HEPARAN SULFATE; HEPARANASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANION TRANSPORT; ARTICLE; CONTROLLED STUDY; ENZYME MODIFICATION; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS EPITHELIUM; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA;

EID: 38149061339     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002706     Document Type: Article

References (49)

1. Esko JD, Selleck SB. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem 2002; 71: 435-471.
2. Turnbull J, Powell A, Guimond S. Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol 2001; 11: 75-82.
3. Daniels BS. Increased albumin permeability in vitro following alterations of glomerular charge is mediated by the cells of the filtration barrier. J Lab Clin Med 1994; 124: 224-230.
4. Kanwar YS, Linker A, Farquhar MG. Increased permeability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparan sulfate) by enzyme digestion. J Cell Biol 1980; 86: 688-693.
5. Kanwar YS, Rosenzweig LJ, Kerjaschki DI. Glycosaminoglycans of the glomerular basement membrane in normal and nephrotic states. Ren Physiol 1981; 4: 121-130.
6. Rosenzweig LJ, Kanwar YS. Removal of sulfated (heparan sulfate) or nonsulfated (hyaluronic acid) glycosaminoglycans results in increased permeability of the glomerular basement membrane to 125I-bovine serum albumin. Lab Invest 1982; 47: 177-184.
7. Miettinen A, Stow JL, Mentone S et al. Antibodies to basement membrane heparan sulfate proteoglycans bind to the laminae rarae of the glomerular basement membrane (GBM) and induce subepithelial GBM thickening. J Exp Med 1986; 163: 1064-1084.
8. van den Born J, van den Heuvel LP, Bakker MA et al. A monoclonal antibody against GBM heparan sulfate induces an acute selective proteinuria in rats. Kidney Int 1992; 41: 115-123.
9. Raats CJ, Luca ME, Bakker MA et al. Reduction in glomerular heparan sulfate correlates with complement deposition and albuminuria in active Heymann nephritis. J Am Soc Nephrol 1999; 10: 1689-1699.
10. Raats CJ, Bakker MA, van den Born J et al. Hydroxyl radicals depolymerize glomerular heparan sulfate in vitro and in experimental nephrotic syndrome. J Biol Chem 1997; 272: 26734-26741.
11. Tamsma JT, van den Born J, Bruijn JA et al. Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane. Diabetologia 1994; 37: 313-320.
12. van Bruggen MC, Kramers K, Hylkema MN et al. Decrease of heparan sulfate staining in the glomerular basement membrane in murine lupus nephritis. Am J Pathol 1995; 146: 753-763.
13. van den Born J, van den Heuvel LP, Bakker MA et al. Distribution of GBM heparan sulfate proteoglycan core protein and side chains in human glomerular diseases. Kidney Int 1993; 43: 454-463.
14. Raats CJ, Bakker MA, Hoch W et al. Differential expression of agrin in renal basement membranes as revealed by domain-specific antibodies. J Biol Chem 1998; 273: 17832-17838.
15. Levidiotis V, Kanellis J, Ierino FL et al. Increased expression of heparanase in puromycin aminonucleoside nephrosis. Kidney Int 2001; 60: 1287-1296.
16. Levidiotis V, Freeman C, Tikellis C et al. Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis. J Am Soc Nephrol 2004; 15: 68-78.
17. Levidiotis V, Freeman C, Tikellis C et al. Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease. Nephrology (Carlton) 2005; 10: 167-173.
18. Kramer A, van den Hoven M, Rops A et al. Induction of glomerular heparanase expression in rats with adriamycin nephropathy is regulated by reactive oxygen species and the renin-angiotensin system. J Am Soc Nephrol 2006; 17: 2513-2520.
19. Maxhimer JB, Somenek M, Rao G et al. Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes 2005; 54: 2172-2178.
20. van den Hoven MJ, Rops AL, Bakker MA et al. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int 2006; 70: 2100-2108.
21. van den Hoven MJ, Rops AL, Vlodavsky I et al. Heparanase in glomerular diseases. Kidney Int 2007; 72: 543-548.
22. Wijnhoven TJ, Lensen JF, Wismans RG et al. In vivo degradation of heparan sulfates in the glomerular basement membrane does not result in proteinuria. J Am Soc Nephrol 2007; 18: 823-832.
23. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006; 38: 2018-2039.
24. Abboud-Jarrous G, Rangini-Guetta Z, Aingorn H et al. Site-directed mutagenesis, proteolytic cleavage, and activation of human proheparanase. J Biol Chem 2005; 280: 13568-13575.
25. Okada Y, Yamada S, Toyoshima M et al. Structural recognition by recombinant human heparanase that plays critical roles in tumor metastasis. Hierarchical sulfate groups with different effects and the essential target disulfated trisaccharide sequence. J Biol Chem 2002; 277: 42488-42495.
26. Pikas DS, Li JP, Vlodavsky I et al. Substrate specificity of heparanases from human hepatoma and platelets. J Biol Chem 1998; 273: 18770-18777.
27. Zcharia E, Metzger S, Chajek-Shaul T et al. Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. FASEB J 2004; 18: 252-263.
28. van den Born J, Jann K, Assmann KJ et al. N-acetylated domains in heparan sulfates revealed by a monoclonal antibody against the Escherichia coli K5 capsular polysaccharide. Distribution of the cognate epitope in normal human kidney and transplant kidney with chronic vascular rejection. J Biol Chem 1996; 271: 22802-22809.
29. van den Born J, Gunnarsson K, Bakker MA et al. Presence of N-unsubstituted glucosamine units in native heparan sulfate revealed by a monoclonal antibody. J Biol Chem 1995; 270: 31303-31309.
30. Jenniskens GJ, Oosterhof A, Brandwijk R et al. Heparan sulfate heterogeneity in skeletal muscle basal lamina: demonstration by phage display-derived antibodies. J Neurosci 2000; 20: 4099-4111.
31. Kurup S, Wijnhoven TJ, Jenniskens GJ et al. Characterization of antiheparan sulfate phage-display antibodies AO4B08 and HS4E4. J Biol Chem 2007; 282: 21032-21042.
32. Dennissen MA, Jenniskens GJ, Pieffers M, et al. Large, tissue-regulated domain diversity of heparan sulfates demonstrated by phage display antibodies. J Biol Chem 2002; 277: 10982-10986.
33. van Kuppevelt TH, Dennissen MA, van Venrooij WJ et al. Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney. J Biol Chem 1998; 273: 12960-12966.
34. Wijnhoven TJ, Lensen JF, Rops AL et al. Aberrant heparan sulfate profile in the human diabetic kidney offers new clues for therapeutic glycomimetics. Am J Kidney Dis 2006; 48: 250-261.
35. Smetsers TF, van de Westerlo EM, ten Dam GB et al. Human single-chain antibodies reactive with native chondroitin sulfate detect chondroitin sulfate alterations in melanoma and psoriasis. J Invest Dermatol 2004; 122: 707-716.
36. van Kuppevelt TH, Veerkamp JH. Application of cationic probes for the ultrastructural localization of proteoglycans in basement membranes. Microsc Res Tech 1994; 28: 125-140.
37. Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 2001; 1471: M99-M108.
38. Vlodavsky I, Goldshmidt O. Properties and function of heparanase in cancer metastasis and angiogenesis. Haemostasis 2001; 31(Suppl 1): 60-63.
39. Li JP, Galvis ML, Gong F et al. In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. Proc Natl Acad Sci USA 2005; 102: 6473-6477.
40. Raats CJ, van den Born J, Berden JH. Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. Kidney Int 2000; 57: 385-400.
41. Chen S, Holzman L, Yamaguchi Y et al. Elimination of heparan sulfate glycosaminoglycans (HS-GAGs) from the glomerular basement membrane (GBM) using Cre-Lox technology has profound effect on podocyte ultrastructure and function [Abstract]. J Am Soc Nephrol 2006; 17: 25A.
42. Harvey SJ, Jarad G, Cunningham J et al. Disruption of glomerular basement membrane charge through podocyte-specific mutation of agrin does not alter glomerular permselectivity. Am J Pathol 2007; 171: 139-152.
43. Morita H, Yoshimura A, Inui K et al. Heparan sulfate of perlecan is involved in glomerular filtration. J Am Soc Nephrol 2005; 16: 1703-1710.
44. Rossi M, Morita H, Sormunen R et al. Heparan sulfate chains of perlecan are indispensable in the lens capsule but not in the kidney. EMBO J 2003; 22: 236-245.
45. Levidiotis V, Freeman C, Punler M et al. A synthetic heparanase inhibitor reduces proteinuria in passive Heymann nephritis. J Am Soc Nephrol 2004; 15: 2882-2892.
46. Assmann KJ, Tangelder MM, Lange WP et al. Anti-GBM nephritis in the mouse: severe proteinuria in the heterologous phase. Virchows Arch A Pathol Anat Histopathol 1985; 406: 285-299.
47. Assmann KJ, Tangelder MM, Lange WP et al. Membranous glomerulonephritis in the mouse. Kidney Int 1983; 24: 303-312.
48. van de Lest CH, Versteeg EM, Veerkamp JH et al. Quantification and characterization of glycosaminoglycans at the nanogram level by a combined azure A-silver staining in agarose gels. Anal Biochem 1994; 221: 356-361.
49. van den Born J, van Kraats AA, Bakker MA et al. Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with streptozotocin-induced diabetic nephropathy. Diabetologia 1995; 38: 1169-1175.